Recent News

• 05.06.2026 - MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.06.2026 - MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
• 04.29.2026 - MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
• 03.09.2026 - MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
• 03.05.2026 - MannKind Announces Settlement of Convertible Senior Notes
• 03.04.2026 - MannKind to Participate in Upcoming Investor Conferences

Recent Filings

• 04.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2026 - ARS Annual Report to Security Holders
• 04.07.2026 - DEF 14A Other definitive proxy statements
• 04.07.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities